PAA Stock Overview
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
PharmAust Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.089 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.062 |
| Beta | 0.59 |
| 1 Month Change | 43.55% |
| 3 Month Change | 12.66% |
| 1 Year Change | -8.25% |
| 3 Year Change | -5.32% |
| 5 Year Change | 28.99% |
| Change since IPO | 5.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| PAA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 7.2% | -5.5% | 1.4% |
| 1Y | -8.2% | -23.5% | 3.8% |
Return vs Industry: PAA exceeded the Australian Pharmaceuticals industry which returned -25.7% over the past year.
Return vs Market: PAA underperformed the Australian Market which returned 0.5% over the past year.
Price Volatility
| PAA volatility | |
|---|---|
| PAA Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.9% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PAA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: PAA's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Roger Aston | https://www.pharmaust.com |
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer.
PharmAust Limited Fundamentals Summary
| PAA fundamental statistics | |
|---|---|
| Market Cap | AU$28.47m |
| Earnings (TTM) | -AU$1.71m |
| Revenue (TTM) | AU$4.51m |
6.3x
P/S Ratio-16.7x
P/E RatioIs PAA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PAA income statement (TTM) | |
|---|---|
| Revenue | AU$4.51m |
| Cost of Revenue | AU$314.34k |
| Gross Profit | AU$4.20m |
| Other Expenses | AU$5.90m |
| Earnings | -AU$1.71m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0053 |
| Gross Margin | 93.03% |
| Net Profit Margin | -37.87% |
| Debt/Equity Ratio | 2.7% |
How did PAA perform over the long term?
See historical performance and comparison